Four serum biochemical fetoplacental function tests (HPL, unconjugated and total oestriol and AFP) were used to screen for intrauterine growth retardation in 793 patients attending an antenatal clinic. The birthweight corrected for sex, birth ranking and maternal size was used as an index of growth. The sensitivity and specificity of each test was calculated at varying cut-off points and plotted as 'Receiver Operator Curves'. HPL is clearly better than the oestriols or AFP with 80% sensitivity in detecting birth weights of less than the 5th centile when the 25th HPL centile is used as the cut-off point. However, the sensitivity of HPL is sufficiently low to make the value of screening questionable, particularly since 40% of all growth retarded infants were in mothers who did not attend antenatal clinic for screening and 25% of all growth retarded infants were detected by clinical examination.
When biochemical fetoplacental function tests (BFPT) were first introduced they were used extensively to assist in the management of patients with a known risk of fetal mortality or morbidity. This use of BFPTs in such situations has been superceded by ultrasound and cardiotachography, and in the Birmingham Maternity Hospital BFPTs for this purpose were discontinued in 1982. However, it is also advocated that BFPTs might be used as a screening test to identify groups of patients at risk of intrauterine growth retardation (IUOR).1-3 The objective of this screening is to provide more intensive antenatal care to the identified high risk group. This changed use of the test raises the questions:
(1) How should the test be interpreted to attain maximum benefit? (2) What is the value of such a test in routine antenatal care? This study looks at the interpretation and value of measuring human placental lactogen (HPL), unconjugated oestriol (UNE3), total oestriol (TE3) and alpha fetoprotein (AFP) to detect IUOR, in an out-patient population in the third trimester of pregnancy. Although there have been many previous studies 2 on the use of these analytes in the third trimester many 264 have been carried out on selected populations and few allow true analysis of the value of such a test in unselected populations, quantifying the failures of the test as well as the success. In fact, only recently have medical statisticians moved from interpreting such tests by statistical analysis of the 'normal' population and hence allow the assessment of value. This paper utilises the statistical techniques of Galen and Gambino" to measure the sensitivity and specificity of these tests in detecting IUGR and to produce receiver operator curves (ROC's).
ROC's are constructed by plotting sensitivity against I-specificity. A good test, with high sensitivity and specificity will fall in the top left hand comer of the graph. As the specificity and sensitivity fall the ROC moves towards the 45°l ine. An ROC on the 45°line indicates that random allocation of results (i.e, chance) would be as effective as carrying out the test (Fig. 1) .
This technique has three functions: (1) It reduces a large amount of data into a clear interpretable graph. (2) It can be used to optimise reference ranges.
(3) It can be used to compare different tests for the same disorder. This paper concentrates on the statistical analysis of data derived from a clinical popula-tion. However, in normal antenatal practice, some patients are not screened because of defaulting, premature delivery or hospital admission. In order to assess the overall impact of a screening test on the entire antenatal population the clinical outcome of this unscreened group needs to be considered. For this reason the patients who booked with the consultant groups under study, but who did not have blood taken, for whatever reason, were also followed up.
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FIG. I. Receiver
Operator Curves (ROC's) are plots of sensitivity against I-specificity. Thc more effective a test the more the ROC will he displaced to the upper left segment of the graph, i.c. the further the curve is displaced to the upper left segment the better the test is at discriminating between patients with and without the disorder being investigated.
The 45°line is the line at which the test performs no better than random selection of an equivalent size group from thc population. Below the 45°line patients with the disorder being investigated have a greater chance than the reference population of having a result within the reference range.
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Patients and methods Over an 18-month period, a total of 1128 unselected women booked with two consultants were studied. Blood samples were taken from 793 patients between 28 and 40 weeks gestation at each routine antenatal clinic visit (these patients will be referred to as the 'screened' population). There were also 335 patients who booked with the same two consultants over the same time period and did not attend the antenatal clinic. There were, therefore, no samples from this group (these patients will be referred to as the 'non-screened' group). A total of 1359 samples were collected from the former group and the serum was stored at -2()OC for the subsequent analysis of HPL, UNE3, TE3 and AFP. No biochemical results were reported to clinicians during the study.
Gestational age was calculated from both the LMP and the ultrasound measurements at the first booking appointment. Where these dates differed significantly, gestation was calculated from a confirmatory ultrasound measurement.
Small for gestational age (SGA) was assessed in two ways: a birth weight of less than the 5th centile for gestational age (SGA 5) and less than the 10th centile for gestational age (SGA 10). All birth weights were fully corrected for sex, birth ranking and maternal size."
Multiple births, intrauterine death (IUD) and patients for whom the biochemical and clinical data was incomplete were excluded from the statistical analysis as live birth weight was used to indicate IUGR. An outline of details of the patients studied is given in Table 1 .
The 46 patients with infants SGA 10 in the 'non-screened' population were further investigated to determine the reasons for the absence of blood samples from these patients. These were identified as:
(1) The patient delivered before the last trimester antenatal clinic appointment (20 patients). (2) The patient was an in-patient during the third tnmester of pregnancy and was not available to attend the out-patient clinic (19 patients). (3) The patient was booked under the care of their general practitioner and transferred shortly before delivery (one patient). (4) The patient did not attend the antenatal clinic (six patients). Clinical detection of SGA 5 infants was assessed retrospectively and was defined as a patient who had a recorded entry of 'small for dates' in the medical record and a management decision as a result of that recorded entry. The management decision was either an ultrasound assessment, admission or altered management of labour. ANALYTICAL 
METHODS
Serum HPL and TE3 were analysed using commercial methods (Radiochemical Centre, Amersham, Bucks, UK) serum UNE3 and AFP were assayed using 'in-house' methods, UNE3 following extraction and based on the partition radioimmunoassay method" and serum AFP was based on the polyethylene glycol (PEG) separation radioimmunoassay technique." During the course of the study both internal and external quality assessment was carried out and coefficients of variation of less than 7% were achieved for all analyses.
Results
Over the period of study there were 1144 live births-805 in the 'screened' population and 339 in the 'non-screened' population. The patient details with the percentage of infants of normal birth weight and SGA infants in each population are shown in Table 1 .
The 5th, 10th and 25th (75th, 90th and 95th for AFP) centile for each biochemical parameter at different gestations were derived for the screened population ( Table 2 ).
The 5th, 10th, and 25th (75th, 90th and 95th for AFP) centile of each test was then used as a reference value to calculate the specificity and sensitivity of the test in the detection of SGA 5 and SGA 10 infants. The sensitivity of the test was defined as the percentage of biochemical results outside the reference value in SGA 5 and SGA 10 infants. The specificity of the test was defined as the percentage of biochemical results inside the reference value in the normal birth weight infants. A patient was considered to have a positive biochemical result if one or more test results on any sample for that parameter fell outside the centile being investigated.
The ROes for each test at each gestation grouping and for SGA 5 and SGA 10 infants were constructed (Fig. 2) . The ROes indicate that HPL has a higher sensitivity and specificity than the other three tests in detecting IUGR because. with the exception of 30-32 week gestation for SGA to infants, the HPL ROC's arc displaced furthest to the left.
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In order to give an indication of the intraindividual changes in classification of positive or negative biochemical results between antenatal clinic visits, the 44 patients with infants of less than the 10th centile, who had more than one sample taken, were further analysed. The The three points on each curve are the calculated sensitivity and specificity using differing reference ranges (Sth, 10th and 25th centile for HPL, UNE3 and TE3 and 75th, 90th and 95th centile for AFP). Two definitions of low birth weight are used, less than the 5th ( Fig. 2A) and less than the 10th birth weight centiles (Fig 28) . The higher the sensitivity and specificity of a test the further the curve moves towards the left upper corner of the graph. The least effective tests are nearer to the 45°line (----).
paired results were placed into one of four categories: (I) The result remained within the reference range. (2) The first result was outside the reference range and the second within. (3) The first result was inside the reference range and the second out"ide. (4) The results were both outside the reference range. The results are shown in Table 3 . The second test in all parameters did little to improve the effectiveness of the test since, with the exception of AFP, similar numbers of patients moved outside the reference range to those which moved back into the reference range.
Since the determination of HPL appears better at detecting (UGR, the data on HPL are discussed in more detail. After the 32nd week of gestation, using the 25th centile as the reference value, HPL detects SGA 5 infants with an 80% sensitivity and a 78% specificity. Therefore, the data indicate that in a group of 1000 unselected pregnancies:
(1) 50 babies will be SGA 5 infants.
(2) 250 pregnancies will have serum HPL levels less than the 25th centile. (3) of the 50 SGA 5 infants, 40 (i.e. 80% sensitivity) will have serum HPL levels less than the 25th centile and 10 will have a HPL within the reference range. (4) therefore, only 40 out of 250 low HPL results will be found to be associated with SGA 5 infants, i.e. only one in every six patients with an HPL less than the 25th centile will have an infant of less than the 5th birthweight centile. If HPL, with the 25th centile as the reference value, were therefore to be used as a screening test. one would need to follow up 25'}'o of the entire antenatal clinic population with either confirmatory test or closer monitoring. The proportion of the population followed up could be reduced to 10%. but at a cost. With the HPL reference value at the 10th centile the sensitivity declines to between 40'X, and 60%. dependent on gestation at testing (for the subsequent calculation we use 50%) and the specificity increases to about 92%.
Therefore. for a group of 1000 unselected pregnancies, the data indicate that: (I) 50 babies will be SGA 5 infants.
(2) 100pregnancies will have serum HPL levels less than the 10th centile. (3) of the 50 SGA 5 infants 25 (i.e. 50% sensitivity) will have serum BPL levels less than the 10th centile and 25 will have HPL levels within the reference ranges. (4) only 25 out of 100 low IIPL results will be found to be associated with SGA 5 infants i.e. only one in every four patients with an HPL less than the 10th centile will have an infant less than the 5th birthweight centile. If IIPL with the 10th centile was. therefore, TABLE 3 . A statistical analysis of the BFPTs on the 44 patients with infants less than the 10th birth weight centile and who had a blood sample taken at more than one antenatal clinic visit. The data shows how the second analysis varies compared to the first. The paired result.'! were placed into four categories (I) 1st and 2nd
(2) Ist result outside (3) used as a screening test. follow-up would be needed on only IO'Y., of the population. but 50% of IUGR infants would be missed. The numbers followed up could be further reduced by using IIPL centiles of less than the 10th as reference values. however. the proportion of IUGR detected would be further reduced. As a reference point the SGA 5 detected by the antenatal clinical examination in the 'screened' antenatal clinic population was assessed retrospectively. Of the 31 infants less than the 5th centile 13 (42%) were detected prior to delivery (NB BFPT values were not reported in this study). Although the techniques used in this study for the assessment of clinical detection of IUGR are somewhat inaccurate the detection rate has been confirmed by similar studies. K. 9
Discussion
Of the BFPTs serum IIPL could be effectively used to select a high risk group (25% of the antenatal clinic population) which would have prevalence of SGA 5 of one in six patients and which would contain 80'Y.. of growth retarded infants. Would such a test be of value'! Since the data show that testing a second sample would not improve the proportion of SGAs detected then in our opinion the selected high risk group with low HPL ought to be followed up with a more definitive ultrasound diagnosis. To offer ultrasound growth assessment to 25'Yo of the third trimester antenatal clinic patients would require considerable resources which would need offsetting against the benefits of detecting the growth retarded infants. With the current treatment of known IUGR being limited in its effectiveness. the benefits which can be offered once it is detected are likewise limited. The detection of IUGR would not seem to justify the major resource investment required. To use serum HPL. therefore. to detect a high risk group is. in our opinion. of very restricted value. However. if serum HPL is of questionable value. then the ROes indicate that TE3. UNE3 and AFP arc of negligible value in the detection of IUGR.
Although the analytical aspects of this study were on an antenatal clinic population it was interesting to observe the higher prevalence of IUGR in the 'non-screened' group. In fact approximately 40% of all the SGA 5 and SGA 10 infants in the study were in this group which could in no way benefit from antenatal clinic screening. In addition approximately 25% of the total (UGR infants were detected by a
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straightforward clinical examination in the antenatal clinic. A screening procedure using HPL in an antenatal clinic population could. therefore. only contribute to the clinical management of a proportion of the 35% of patients with lUGR infants who would. otherwise. proceed through the antenatal clinic without intervention.
The restricted use of BFPT in screening for (UGR in an unselected antenatal population raises the question-are there any circumstances when BFPT could be of any clinical value'! In monitoring a pregnancy, serial values may give more information than a 'one off biochemical result. but whichever method of assessment is used there is a delay resulting from analysis time. In contrast if cardiotachography and ultrasound services are provided more comprehensive information about the welfare of the fetus is immediately available to the clinician. Thus there are very few acute circumstances when any BFPT could contribute significantly to the clinical assessment of identified at risk pregnancies. This paper has also demonstrated that a large proportion of antenatal patients with IUGR do not benefit from screening tests in the antenatal clinic. Justification for continuing to supply a laboratory service for BFPT is the responsibility of the management of individual obstetric units. However, in our own obstetric unit where cardiotachography and ultrasound services are available we regard BFPT as obsolete and the perpetuation of an analytical service for these tests would be a waste of resources better allocated elsewhere.
